ID   STS-26T
AC   CVCL_8917
SY   STS26T; STS26
DR   BTO; BTO:0003226
DR   EFO; EFO_0006296
DR   Cosmic; 1644551
DR   Cosmic; 1801813
DR   Cosmic; 2307728
DR   DepMap; ACH-002695
DR   Wikidata; Q54970640
RX   PubMed=8094415;
RX   PubMed=9766530;
RX   PubMed=16239399;
RX   PubMed=16510576;
RX   PubMed=21084276;
RX   PubMed=22346343;
RX   PubMed=23437333;
RX   PubMed=24726063;
RX   PubMed=28469964;
RX   PubMed=28556483;
RX   PubMed=32642732;
RX   PubMed=33707600;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~16 hours (PubMed=21084276).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=21084276).
CC   Derived from site: Metastatic; Bone, left scapula; UBERON=UBERON_0006849.
ST   Source(s): PubMed=28556483; PubMed=33707600
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 9,10
ST   D16S539: 12,13
ST   D18S51: 17,18
ST   D19S433: 14
ST   D21S11: 30,31 (PubMed=28556483)
ST   D21S11: 31 (PubMed=33707600)
ST   D2S1338: 20
ST   D3S1358: 14 (PubMed=28556483)
ST   D3S1358: 14,20 (PubMed=33707600)
ST   D5S818: 11,12
ST   D7S820: 8,11
ST   D8S1179: 13,14
ST   FGA: 22,23
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3798; Malignant peripheral nerve sheath tumor
DI   ORDO; Orphanet_3148; Malignant peripheral nerve sheath tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 23
//
RX   PubMed=8094415; DOI=10.1080/09553009314550251;
RA   Dahlberg W.K., Little J.B., Fletcher J.A., Suit H.D., Okunieff P.;
RT   "Radiosensitivity in vitro of human soft tissue sarcoma cell lines and
RT   skin fibroblasts derived from the same patients.";
RL   Int. J. Radiat. Biol. 63:191-198(1993).
//
RX   PubMed=9766530; DOI=10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9;
RA   Badache A., de Vries G.H.;
RT   "Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived
RT   growth factor (PDGF) receptors and are induced to proliferate by PDGF
RT   BB.";
RL   J. Cell. Physiol. 177:334-342(1998).
//
RX   PubMed=16239399; DOI=10.1124/jpet.105.091454;
RA   Mattingly R.R., Kraniak J.M., Dilworth J.T., Mathieu P., Bealmear B.,
RA   Nowak J.E., Benjamins J.A., Tainsky M.A., Reiners J.J. Jr.;
RT   "The mitogen-activated protein kinase/extracellular signal-regulated
RT   kinase kinase inhibitor PD184352 (CI-1040) selectively induces
RT   apoptosis in malignant schwannoma cell lines.";
RL   J. Pharmacol. Exp. Ther. 316:456-465(2006).
//
RX   PubMed=16510576; DOI=10.1158/0008-5472.CAN-05-3330;
RA   Miller S.J., Rangwala F., Williams J., Ackerman P., Kong S.,
RA   Jegga A.G., Kaiser S., Aronow B.J., Frahm S., Kluwe L., Mautner V.-F.,
RA   Upadhyaya M., Muir D.F. IV, Wallace M.R., Hagen J., Quelle D.E.,
RA   Watson M.A., Perry A., Gutmann D.H., Ratner N.;
RT   "Large-scale molecular comparison of human Schwann cells to malignant
RT   peripheral nerve sheath tumor cell lines and tissues.";
RL   Cancer Res. 66:2584-2591(2006).
//
RX   PubMed=21084276; DOI=10.1158/0008-5472.CAN-10-2799;
RA   Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R.,
RA   Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J.,
RA   Lev D.C.;
RT   "Autophagic survival in resistance to histone deacetylase inhibitors:
RT   novel strategies to treat malignant peripheral nerve sheath tumors.";
RL   Cancer Res. 71:185-196(2011).
//
RX   PubMed=22346343; DOI=10.4137/TOG.S8830;
RA   Sun D., Tainsky M.A., Haddad R.;
RT   "Oncogene mutation survey in MPNST cell lines enhances the dominant
RT   role of hyperactive Ras in NF1 associated pro-survival and
RT   malignancy.";
RL   Transl. Oncogenomics 5:1-7(2012).
//
RX   PubMed=23437333; DOI=10.1371/journal.pone.0057152;
RA   Reuss D.E., Mucha J., Hagenlocher C., Ehemann V., Kluwe L.,
RA   Mautner V.-F., von Deimling A.;
RT   "Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL
RT   is augmented by loss of NF1 through modulation of MYC/MAD and is
RT   potentiated by curcumin through induction of ROS.";
RL   PLoS ONE 8:E57152-E57152(2013).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
//
RX   PubMed=28469964;
RA   Guo J.-M., Grovola M.R., Xie H., Coggins G.E., Duggan P., Hasan R.,
RA   Huang J.-L., Lin D.W., Song C., Witek G.M., Berritt S., Schultz D.C.,
RA   Field J.;
RT   "Comprehensive pharmacological profiling of neurofibromatosis cell
RT   lines.";
RL   Am. J. Cancer Res. 7:923-934(2017).
//
RX   PubMed=28556483; DOI=10.1002/1878-0261.12086;
RA   Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H.,
RA   Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P.,
RA   Lothe R.A.;
RT   "Drug sensitivity and resistance testing identifies PLK1 inhibitors
RT   and gemcitabine as potent drugs for malignant peripheral nerve sheath
RT   tumors.";
RL   Mol. Oncol. 11:1156-1171(2017).
//
RX   PubMed=32642732; DOI=10.1093/noajnl/vdz049;
RA   Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.;
RT   "Genetics of human malignant peripheral nerve sheath tumors.";
RL   Neurooncol. Adv. 2:I50-I61(2020).
//
RX   PubMed=33707600; DOI=10.1038/s41598-021-85055-2;
RA   Longo J.F., Brosius S.N., Znoyko I., Alers V.A., Jenkins D.P.,
RA   Wilson R.C., Carroll A.J. III, Wolff D.J., Roth K.A., Carroll S.L.;
RT   "Establishment and genomic characterization of a sporadic malignant
RT   peripheral nerve sheath tumor cell line.";
RL   Sci. Rep. 11:5690-5690(2021).
//